scispace - formally typeset
J

Jolanta B. Zawilska

Researcher at Medical University of Łódź

Publications -  68
Citations -  2141

Jolanta B. Zawilska is an academic researcher from Medical University of Łódź. The author has contributed to research in topics: Melatonin & Pineal gland. The author has an hindex of 22, co-authored 64 publications receiving 1804 citations. Previous affiliations of Jolanta B. Zawilska include Polish Academy of Sciences.

Papers
More filters
Journal ArticleDOI

Physiology and pharmacology of melatonin in relation to biological rhythms.

TL;DR: This review surveys the current state of knowledge regarding the regulation of melatonin synthesis, receptor expression, and function and addresses the physiological, pathological, and therapeutic aspects ofmelatonin in humans, with an emphasis on biological rhythms.
Journal ArticleDOI

Designer cathinones--an emerging class of novel recreational drugs.

TL;DR: This review surveys the current state of knowledge regarding the pharmacotoxicological properties of synthetic cathinones, the prevalence and pattern of their use, and the negative consequences of using these products including, among others, cardiovascular, psychiatric and neurologic symptoms, dehydration, rhambdomyolysis, renal and liver failure.
Journal ArticleDOI

Next generation of novel psychoactive substances on the horizon - A complex problem to face.

TL;DR: This review presents updated information on the second generation of NPS, introduced as replacements of the already banned substances from this class, focusing on their pharmacological properties and metabolism, routes of administration, and effects in humans.
Journal ArticleDOI

An Expanding World of Novel Psychoactive Substances: Opioids.

TL;DR: An overview of the pharmacological properties, pattern of use, and desired and unwanted effects of the above-listed novel opioids is provided.
Journal ArticleDOI

Abuse of fentanyl: An emerging problem to face.

TL;DR: As the fentanyl problem is constantly growing, there is an urgent need for new, effective harm-reduction strategies and technologies, as well as overdose maintenance.